Mark Lockwood

Dr. Lockwood has 20+ years of experience in the pharmaceutical industry in both process and medicinal chemistry. He began his pharmaceutical career at Abbott Laboratories, where he was part of the process chemistry group responsible for bringing Kaletra to market. He moved from large pharma to be a part of several startup biotech companies in the Atlanta area, including Somatacor Pharmaceuticals, AtheroGenics, Metastatix, and the Emory Institute for Drug Development, where he developed a process for the manufacture of molnupiravir, an antiviral drug licensed to Ridgeback (and later Merck). Molnupiravir is currently in phase 2/3 clinical trials for the treatment of COVID-19. Dr. Lockwood is currently the Director of Process Research and Manufacturing at Antios Therapeutics and is the coauthor of numerous scientific publications and patents.

Dr. Lockwood received his Ph.D. from Purdue University and was a post-doctoral associate at the University of Washington.